Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as NY-ESO-1(c259)T Cells
NY-ESO-1T Cells · 1 trial · 1 indication
ORR was calculated as the percentage of participants with a confirmed complete response (CR) or partial response (PR) relative to the total number of participants in the analysis population per response evaluation criteria in solid tumors (RECIST) version (v)1.1 as determined by the local investigators.
| Arm | Type | Description |
|---|---|---|
| Cohort 1 treated with NY-ESO-1 T Cells | EXPERIMENTAL | High NY-ESO-1 expression and the use of cyclophosphamide plus fludarabine as the lymphodepleting chemotherapy. |
| Cohort 2 treated with NY-ESO-1 T Cells | EXPERIMENTAL | Low NY-ESO-1 expression and the use of cyclophosphamide plus fludarabine as the lymphodepleting chemotherapy. |
| Cohort 3 treated with NY-ESO-1 T Cells | EXPERIMENTAL | High NYESO-1 expression and the use of cyclophosphamide only for lymphodepletion rather than fludarabine as the lymphodepleting chemotherapy. |
| Cohort 4 treated with NY-ESO-1 T Cells | EXPERIMENTAL | High NY-ESO-1 expression and the use of reduced dose cyclophosphamide plus fludarabine regimen as the lymphodepleting chemotherapy. |
| Name | Type | Description |
|---|---|---|
| NY-ESO-1(c259)T Cells | DRUG | Lymphodepleting chemotherapy followed by infusion with NY-ESO-1(c259) transduced autologous T cells. Subjects will receive one infusion of NY-ESO-1 genetically engineered T cells on Day 0. |
| Fludarabine | DRUG | Fludarabine will be used as lymphodepleting chemotherapy. |
| Cyclophosphamide | DRUG | Cyclophosphamide will be used as lymphodepleting chemotherapy. |
Inclusion Criteria: * Synovial sarcoma that has been treated with standard chemotherapy containing ifosfamide and/or doxorubicin and remains: unresectable or metastatic or progressive/persistent or recurrent disease * Measurable disease * Patients must have proven positive tumor sample for NY-ESO-1...
Top 14 of 16 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Bristol-Myers Squibb Company | BMY | 5 | PHASE3 | Luspatercept, Fedratinib, BMS-986158 |
| AbbVie, Inc. | ABBV | 4 | PHASE3 | Navitoclax, ABBV-744, IMGN632 |
| Novartis AG Sponsored ADR | NVS | 3 | PHASE3 | Pelabresib, Ruxolitinib |
| Karyopharm Therapeutics, Inc. | KPTI | 4 | PHASE3 | Selinexor |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 2 | PHASE3 | Elritercept |
| Geron Corporation | GERN | 2 | PHASE3 | Imetelstat |
| Incyte Corporation | INCY | 8 | PHASE2 | Ruxolitinib, INCB160058, INCB057643, INCA033989, INCA036978 |
| Merck & Co., Inc. | MRK | 1 | PHASE3 | Bomedemstat |
| GSK plc Sponsored ADR | GSK | 3 | PHASE2 | Momelotinib |
| Eli Lilly and Company | LLY | 2 | PHASE1 | LY3410738, LY5830966 |
| Disc Medicine, Inc. | IRON | 1 | PHASE1 | DISC-0974 |
| Damora Therapeutics, Inc. | DMRA | 2 | PHASE2 | GB2064, DMR-001 |
| Prelude Therapeutics, Inc. | PRLD | 1 | PHASE1 | PRT12396 |
| Syndax Pharmaceuticals Inc | SNDX | 1 | PHASE1 | Revumenib |
NY-ESO-1T Cells is an investigational cell therapy being studied in oncology for neoplasms, including synovial sarcoma. It is a genetically engineered T cell product designed to recognize the NY-ESO-1 cancer-testis antigen in patients who are HLA-A2 positive. It is also known as NY-ESO-1(c259)T Cells.
NY-ESO-1T Cells is being studied for the treatment of neoplasms, specifically in HLA-A2 positive patients with synovial sarcoma. The clinical program is biomarker-selected, meaning patients are chosen based on HLA-A2 status and NY-ESO-1 expression rather than an unselected population.
NY-ESO-1T Cells is being developed by GSK plc, which trades under the ticker GSK. The company is the sponsor behind the clinical program evaluating this engineered T cell therapy in biomarker-selected cancer patients.
NY-ESO-1T Cells is in Phase 1 clinical development. It is an investigational therapy and has not been approved by the FDA. The Phase 1 program has completed, with one trial conducted in the United States enrolling 50 patients.
NY-ESO-1T Cells has been evaluated in one Phase 1 trial, NCT01343043, titled a pilot study of genetically engineered NY-ESO-1 specific NY-ESO-1(c259)T in HLA-A2 positive patients with synovial sarcoma. The trial is completed, enrolled 50 patients, was controlled, and included patients aged 4 years and older.
Yes, NY-ESO-1T Cells is also known as NY-ESO-1(c259)T Cells. The two names refer to the same genetically engineered T cell therapy developed by GSK plc, so searches under either name point to the same investigational oncology asset.